Vivo Capital LLC

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Vivo Capital LLC
CRD #159868
SEC #801-79829
CIK #0000167471, 0001674712
AUM 6,095.6 M (2026-03-31)
Employees 62 (52% Investors, 0% Brokers)
Fees
Minimum
Phone650-688-0818
Address192 Lytton Avenue
Palo Alto, CA 94301
Source [IAPD] [EDGAR] [Website] [Twitter] [LinkedIn] [Facebook]
Total AUM ($B)
7.56.04.53.01.50.02010201520212027
In the News
Fri, 31 Jul 2026 Bright Minds Biosciences Inc. $DRUG Shares Bought by Vivo Capital LLC — MarketBeat
Fri, 31 Jul 2026 Abivax SA Sponsored ADR $ABVX Shares Sold by Vivo Capital LLC — MarketBeat
Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure]
Item 5 – Fees and Compensation

A. Interests in the Funds were only offered to “accredited investors” as defined in Rule 501 under
   Regulation D promulgated under the Securities Act of 1933, as amended (the “Securities Act”), or
   “qualified purchasers” as defined in the Investment Company Act of 1940, as amended (the
   “Investment Company Act”). Vivo and/or its affiliates generally receive management fees and
   performance fees for providing advisory services to the Funds. Investors and prospective investors
   should refer to the Funds’ governing and offering documents for a detailed description of the fees and
   expenses associated with investments in the Funds.

B. Vivo deducts management fees (the “Management Fee”) directly from the Funds’ assets paid
   quarterly in advance. The Firm may also be entitled to a performance fee (the “Carried Interest”),
   based on cumulative net profits from investments, as specified in each Fund’s governing and offering
   documents. The Carried Interest, if applicable, is distributed directly from a Fund’s assets and not on
   a pre-determined schedule. Management Fees will vary amongst the Funds.

C. Each Fund will bear all costs and expenses related to the purchase, holding, sale or exchange of
   portfolio securities, Management Fee, Fund meetings, advisory committee matters, indemnification
   obligations pursuant to the partnership agreement, liability and other insurance premiums for the
   partnership, expenses associated with communications and reports, all legal, accounting and
   regulatory filing fees relating to the Fund and its activities, and any extraordinary expenses of the
   Fund.

    Each Fund will also bear all costs and expenses related to the liquidation of the Fund’s assets upon
    termination of the Fund. Investors and prospective investors should refer to the respective Funds’
    governing and offering documents for a detailed description of the expenses borne by the Funds.

    From time to time, in order to enhance the operations of a Vivo portfolio company and preserve and
    increase the value of the portfolio company, Vivo’s employees may serve as “operating executives”
    on a temporary basis of Vivo portfolio companies. In those occasions, the Vivo employee may enter
    into a consulting or employment agreement with the portfolio company. Such operating executive’s
    compensation from a portfolio company needs to be reasonable and commensurate with the role
    that such operating executive plays at the portfolio company and is determined by the portfolio
    company on an arm’s length basis. Vivo may also charge monitoring fees and/or transaction fees
    where Vivo provides significant back-office support and business development for a portfolio
    company, or syndicates a consortium for a buy-out transaction, and such monitoring fees and
    transaction fees will offset the management fees of each applicable Fund in accordance with the
    Fund’s governing documents.

    Vivo’s employees may also serve on the boards of directors of Vivo portfolio companies and receive
    director fees as a result. Those director fees will offset management fees of each applicable Fund in
    accordance with the Fund’s governing documents.

 Vivo Capital LLC                                          Form ADV Part 2A Brochure            2026

D. Funds are generally required to pay Management Fees quarterly in advance, as specified in each
   Fund’s governing and offering documents. In the event Vivo does not provide services for the full
   period, the Management Fee is typically required to be returned to investors in the applicable Fund.
   In general, the amount of fees returned is calculated based on the number of days remaining in the
   applicable period.

E. Neither Vivo nor any of its supervised persons receive, directly or indirectly, any compensation from
   the sale of securities or other investment products that were purchased by the Funds.
Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure]
Item 7 – Types of Clients

Vivo provides investment advice to the Funds, which are private investment vehicles that are exempt from
registration under the Investment Company Act. The Funds’ investors are limited to individuals and
entities that meet certain suitability criteria including “accredited investors” and “qualified purchasers.”
The Funds were marketed exclusively to institutional investors and high net worth individuals that meet
these criteria.

The minimum investment thresholds in the Funds range from $25,000 to $25 million; however, the
minimum investment may be waived at the discretion of the General Partner of each Fund.

Vivo and/or its affiliates have entered into separate agreements or arrangements (“Side Letters”) with
certain investors in the Funds without the approval of any other investors. The Side Letters may offer
certain investors additional or different rights or terms, including without limitation additional reporting
obligations by the Funds to such investors, disclosure rights of such investors and/or confirmation as to
whether an investor holds an advisory board seat. Also, the Side Letters will provide a customary most
favored nation feature, which may include transparency of the side letters of other investors (or subset
thereof) upon the final closing of the Fund. The Side Letters don’t offer investors with economic rights
different from what is provided in the limited partnership agreement of the Funds.
Sector Form 13F Holdings Value ($B)
Erasca Inc 0.2
Praxis Precision Medicines Inc 0.1
Trevi Therapeutics Inc 0.1
DBV Technologies Sa 0.1
Olivia Ventures Inc 0.1
BCTG Acquisition Corp 0.0
Big Cypress Acquisition Corp 0.0
Corvus Pharmaceuticals Inc 0.0
Bright Minds Biosciences Inc 0.0
Magenta Therapeutics Inc 0.0
View All
Holdings by Sector ($B)
3.02.41.81.20.60.02014201820222027
Type Form D Funds Date Sold AUM
PE Vivo Arrace Fund LP [2025-03-31] 321.3 M
Filed 2024-07-08 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
Other Vivo Asia Spring Limited 2025-03-31 10.0 M
PE Vivo Capital Fund X LP [2024-03-28] 717.0 M 755.1 M
Filed 2026-01-20 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Commission $100,000 · Revenue Decline to Disclose
PE Vivo Co-Invest C LP [2024-03-28] 150.0 M
Filed 2023-10-27 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
Other Vivo Asia Opportunity Fund Holdings LP [2023-03-31] 139.2 M
Filed 2021-12-16 (D) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose
SA Vivo Co-Invest S LP [2023-03-31] 49.8 M
Filed 2022-04-13 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
VC Vivo Innovation Fund II Holdings LP [2023-03-31] 180.0 M 341.0 M
Filed 2022-03-18 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose
Other Vivo Opportunity Fund Holdings LP [2023-03-31] 1,998.9 M
Filed 2021-12-16 (D) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose
PE Vivo Asia Opportunity Fund LP [2022-03-31] 148.5 M 105.4 M
Filed 2025-10-10 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose
VC Vivo Innovation Fund II LP [2021-03-31] 180.0 M 209.0 M
Filed 2022-03-18 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose
View All
AUM Breakdown Accounts AUM ($B)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 16 6.1
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 16 6.1
By Discretionary
Discretionary 16 6.1
Non-Discretionary 0 0.0
Total 16 6.1
By Non-United States Persons
Non-United States Persons 0.4
United States Persons 5.7
Total 16 6.1
Limited Partners2011 - 2026
California State Teachers' Retirement System
Form D Directors Role # Filings # Firms 2011 - 2026
Chen Yu Director 24 3
Gaurav Aggarwal Director, Executive Officer 19 3
Albert Cha Director, Executive Officer 46 2
Frank Kung Director, Executive Officer 45 2
Jack Nielsen Director 44 2
Michael Chang Director, Executive Officer 38 2
Edgar Engleman Director 29 2
Mahendra Shah Director, Executive Officer 26 2
Hongbo Lu Director 17 2
David Liu Director 16 2
View All
EDGAR Form CIK 2011 - 2026
13F-HR [0001674712]
3 [0001674712]
4 [0001674712]
SC 13D [0001674712]
Form 13D/13G Filer Form 13D/13G Subject Filed
Vivo Capital LLC Sinovac Biotech Ltd [2018-07-11]
Firm Profile (Form ADV)
ServesInstitutional
Fund TypesPrivate Equity
LEI25490014X9LPHXWXCC91
Form 3/4/5 Subject 2011 - 2026
Vivo Capital Fund VIII LP
Crinetics Pharmaceuticals Inc
Vivo Capital LLC
Vivo Capital Surplus Fund VIII LP
Vivo Opportunity LLC
Vivo Capital VIII LLC
Vivo Opportunity Fund LP
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Crinetics Pharmaceuticals Inc CRNX
Common Stock
2018-07-20 Conversion 353,590
Crinetics Pharmaceuticals Inc CRNX
Common Stock
2018-07-20 Conversion 2,560,613
Crinetics Pharmaceuticals Inc CRNX
Common Stock
2018-07-20 Buy 153,180 $20.73 3,175,421
Crinetics Pharmaceuticals Inc CRNX
Common Stock
2018-07-20 Buy 141,177 $17.00 2,400,009
Crinetics Pharmaceuticals Inc CRNX
Common Stock
2018-07-20 Buy 7,137 $17.00 121,329
Crinetics Pharmaceuticals Inc CRNX
Common Stock
2018-07-20 Buy 51,686 $17.00 878,662
Crinetics Pharmaceuticals Inc CRNX
Common Stock
2018-07-20 Conversion 413,040
Crinetics Pharmaceuticals Inc CRNX
Common Stock
2018-07-20 Conversion 57,035
Crinetics Pharmaceuticals Inc CRNX
Series A Preferred Stock · derivative
2018-07-20 Conversion 1,163,311
Crinetics Pharmaceuticals Inc CRNX
Series B Preferred Stock · derivative
2018-07-20 Conversion 1,358,903
Crinetics Pharmaceuticals Inc CRNX
Series B Preferred Stock · derivative
2018-07-20 Conversion 187,648
Crinetics Pharmaceuticals Inc CRNX
Series A Preferred Stock · derivative
2018-07-20 Conversion 8,424,416
Comparable Firms State AUM
Riverwood Capital Management LP
CA 6,166.0 M
Tikehau Capital North America LLC
NY 6,163.9 M
A Fin Management LLC
FL 6,160.3 M
Freeman Spogli Management Co LP
CA 6,160.3 M
Lotus Infrastructure Partners LP
CT 6,155.6 M
Primary Wave IP Investment Management LLC
NY 6,136.2 M
Vision Ridge Partners LLC
CO 6,109.8 M
Warren Equity Partners Manager LP
FL 6,088.1 M
Haveli Investment Management LLC
TX 6,031.1 M
Trivest Investment Advisors LLC
FL 6,011.2 M
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com